LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 269

Search options

  1. Article: Demographic, Health, and Exposure Risks Associated With Cognitive Loss, Alzheimer's Disease and Other Dementias in US Military Veterans.

    Zhu, Carolyn W / Sano, Mary

    Frontiers in psychiatry

    2021  Volume 12, Page(s) 610334

    Abstract: The US military veteran population receiving care through the Veterans Health Administration (VHA) is particularly susceptible to cognitive impairment and dementias such as Alzheimer's disease and related dementias due to demographic, clinical, and ... ...

    Abstract The US military veteran population receiving care through the Veterans Health Administration (VHA) is particularly susceptible to cognitive impairment and dementias such as Alzheimer's disease and related dementias due to demographic, clinical, and economic factors. In this report we summarize the prevalence of dementia among US veterans and risks associated with AD and related dementias. We discuss the likelihood that these risks may be increasing in those about to enter the age in which dementias are common. We propose that VHA, the largest integrated health care system in the US, has shown promise in managing health risks that impact dementia prevention and propose further system wide approaches to be assessed for effective dementia prevention and care delivery.
    Language English
    Publishing date 2021-02-25
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2021.610334
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Non-amyloid approaches to neuroprotection.

    Sano, Mary

    CNS spectrums

    2016  Volume 13, Issue 10 Suppl 16, Page(s) 42–44

    MeSH term(s) Alzheimer Disease/diet therapy ; Alzheimer Disease/metabolism ; Alzheimer Disease/prevention & control ; Amyloid beta-Protein Precursor/metabolism ; Anti-Inflammatory Agents/therapeutic use ; Antioxidants/therapeutic use ; Energy Intake ; Estrogens/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
    Chemical Substances Amyloid beta-Protein Precursor ; Anti-Inflammatory Agents ; Antioxidants ; Estrogens ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2016-11-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2008418-3
    ISSN 2165-6509 ; 1092-8529
    ISSN (online) 2165-6509
    ISSN 1092-8529
    DOI 10.1017/s1092852900027073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Apathy in Lewy body disease and its effects on functional impairment over time.

    Zhu, Carolyn W / Grossman, Hillel T / Elder, Gregory A / Rosen, Howie / Sano, Mary

    Frontiers in neurology

    2024  Volume 15, Page(s) 1339190

    Abstract: Background and objectives: Apathy strongly affects function in Alzheimer's disease and frontotemporal dementia, however its effect on function in Lewy Body Disease (LBD) has not been well-described. This study aims to (1) examine the prevalence and ... ...

    Abstract Background and objectives: Apathy strongly affects function in Alzheimer's disease and frontotemporal dementia, however its effect on function in Lewy Body Disease (LBD) has not been well-described. This study aims to (1) examine the prevalence and persistence of apathy in a large, national cohort of well-characterized patients with LBD, and (2) estimate the effect of apathy on function over time.
    Methods: Study included 676 participants with mild cognitive impairment (MCI) or dementia in the National Alzheimer's Coordinating Center Uniform Data Set. Participants were followed for an average of 3.4 ± 1.7 years and consistently had a primary diagnosis of LBD. Apathy was defined by clinician judgment, categorized into four mutually exclusive profiles: (1) never apathetic across all visits, (2) at least one but <50% of visits with apathy (
    Results: Baseline characteristics of the sample were: average age = 72.9 ± 6.9, years of education = 15.6 ± 3.4, Mini Mental State Exam (MMSE) = 24.4 ± 5.4, Geriatric Depression Scale (GDS) = 3.8 ± 3.2, FAQ = 12.0 ± 9.1. 78.8% were male and 89% were non-Hispanic white. Prevalence of apathy increased from 54.4% at baseline to 65.5% in year 4. 77% of participants had apathy at some point during follow-up. Independent of cognitive status and parkinsonian features, FAQ was significantly higher in participants with intermittent/persistent and always apathetic than never apathetic. Annual rate of decline in FAQ was faster in participants who were always apathetic than never apathy.
    Discussion: In this large national longitudinal cohort of LBD patients with cognitive impairment, apathy was strongly associated with greater functional impairment at baseline and faster rate of decline over time. The magnitude of these effects were clinically important and were observed beyond the effects on function from participants' cognitive status and parkinsonism, highlighting the importance of specifically assessing for apathy in LBD.
    Language English
    Publishing date 2024-01-18
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2024.1339190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Apathy and Functional Impairment in the Course of Behavioral Variant Frontotemporal Dementia.

    Zhu, Carolyn W / Grossman, Hillel T / Sano, Mary

    JAMA network open

    2022  Volume 5, Issue 12, Page(s) e2245656

    MeSH term(s) Humans ; Frontotemporal Dementia ; Apathy
    Language English
    Publishing date 2022-12-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2022.45656
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease.

    Knopman, David / Sano, Mary / Feldman, Howard H

    Nature reviews. Neurology

    2022  Volume 18, Issue 7, Page(s) 379–380

    MeSH term(s) Alzheimer Disease/therapy ; Amyloid ; Amyloid beta-Peptides ; Antibodies, Monoclonal/therapeutic use ; Centers for Medicare and Medicaid Services, U.S. ; Humans ; United States
    Chemical Substances Amyloid ; Amyloid beta-Peptides ; Antibodies, Monoclonal
    Language English
    Publishing date 2022-05-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491514-2
    ISSN 1759-4766 ; 1759-4758
    ISSN (online) 1759-4766
    ISSN 1759-4758
    DOI 10.1038/s41582-022-00672-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Response to Schneider and Goldberg "Composite cognitive and functional measures for early stage Alzheimer's disease trials".

    Sano, Mary / Zhu, Carolyn W

    Alzheimer's & dementia (Amsterdam, Netherlands)

    2020  Volume 12, Issue 1, Page(s) e12015

    Language English
    Publishing date 2020-05-15
    Publishing country United States
    Document type Editorial
    ZDB-ID 2832898-X
    ISSN 2352-8729
    ISSN 2352-8729
    DOI 10.1002/dad2.12015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.

    Zhu, Carolyn W / Neugroschl, Judith / Barnes, Lisa L / Sano, Mary

    Alzheimer's & dementia : the journal of the Alzheimer's Association

    2022  Volume 18, Issue 12, Page(s) 2582–2592

    Abstract: Background: Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.: Methods: The study included initially untreated participants followed in National Alzheimer's Coordinating Center ... ...

    Abstract Background: Racial/ethnic disparities in anti-dementia medications use in longitudinally followed research participants are unclear.
    Methods: The study included initially untreated participants followed in National Alzheimer's Coordinating Center Uniform Data Set who were ≥65 at baseline with Alzheimer's disease dementia.
    Outcomes: Outcomes for acetylcholinesterase inhibitor (AChEI) treatment included (1) any new AChEI treatment during follow-up, and (2) persistence of treatment during follow-up categorized into: intermittent treatment (< 50% follow-ups reporting treatment), persistent (≥50% follow-ups), and always treated. Outcomes for memantine treatment were similarly constructed.
    Results: Controlling for participant characteristics, Black and Hispanic participants remained less likely than White participants to report any new AChEI or memantine treatment during follow-up. Among those who reported new treatment during follow-up, both Black and Hispanic participants were less likely than White participants to be persistently treated with AChEI and memantine.
    Discussion: Substantial racial/ethnic treatment disparities remain in controlled settings of longitudinal research in which participants have access to dementia experts, suggesting wider disparities in the larger community.
    MeSH term(s) Humans ; Memantine/therapeutic use ; Acetylcholinesterase/therapeutic use ; Racial Groups ; Alzheimer Disease/drug therapy ; Cholinesterase Inhibitors/therapeutic use ; Healthcare Disparities
    Chemical Substances Memantine (W8O17SJF3T) ; Acetylcholinesterase (EC 3.1.1.7) ; Cholinesterase Inhibitors
    Language English
    Publishing date 2022-02-25
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2211627-8
    ISSN 1552-5279 ; 1552-5260
    ISSN (online) 1552-5279
    ISSN 1552-5260
    DOI 10.1002/alz.12623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.

    Gandy, Sam / Knopman, David S / Sano, Mary

    Molecular neurodegeneration

    2021  Volume 16, Issue 1, Page(s) 74

    MeSH term(s) Alzheimer Disease ; Amyloid beta-Peptides/metabolism ; Antibodies, Monoclonal, Humanized ; Caregivers ; Humans ; Physicians
    Chemical Substances Amyloid beta-Peptides ; Antibodies, Monoclonal, Humanized ; aducanumab (105J35OE21)
    Language English
    Publishing date 2021-11-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2244557-2
    ISSN 1750-1326 ; 1750-1326
    ISSN (online) 1750-1326
    ISSN 1750-1326
    DOI 10.1186/s13024-021-00490-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Never too fit for body and mind.

    Sano, Mary

    Annals of internal medicine

    2013  Volume 158, Issue 3, Page(s) 213–214

    MeSH term(s) Cardiovascular Physiological Phenomena ; Dementia/prevention & control ; Female ; Humans ; Male ; Middle Aged/physiology ; Physical Fitness
    Language English
    Publishing date 2013-02-05
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/0003-4819-158-3-201302050-00013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top